April 2014 Br J Cardiol 2014;21:56–7 Online First
BJCardio Staff
HEAT-PPCI: heparin outperforms bivalirudin in primary PCI The major talking point of this year’s American College of Cardiology meeting was without doubt the aptly named HEAT-PPCI trial which generated more heat than has been seen at such conferences for quite some time. The trial acronym stands for How Effective Are Antithrombotic Therapies in Primary PCI (percutaneous coronary intervention), and the study – conducted in the UK under the leadership of Dr Rod Stables (Liverpool Heart and Chest Hospital) – compared unfractionated heparin with bivalirudin (Angiomax®, the Medicines Company) in patients with ST-elevation myoca
August 2012 Br J Cardiol 2012;19:107–10
BJCardio Staff
“It’s no coincidence that we’re publishing the series at a time when the country and much of the world is gripped with Olympic fever,” stated Dr Pamela Das, executive editor of the Lancet, at a press conference. One paper reported that 9.4% of deaths from any cause are attributable to physical inactivity. Although the host nation of the Olympics, the UK came out particularly badly in the research. In terms of coronary heart disease, lack of exercise was said to account for 5.8% of cases worldwide, but this rises to 10.5% in the UK. If everyone were to engage in just a modest level of physical activity, this would translate into a gain
August 2012 Br J Cardiol 2012;19:112–3
BJCardio Staff
EVINCI study completed The prevalence of “significant” coronary artery disease in patients with chest pain symptoms is lower than expected in Europe, according to preliminary findings from the The EValuation of INtegrated Cardiac Imaging (EVINCI) study. Once the final analysis is completed, the EVINCI study is expected to demonstrate that performing adequate non-invasive imaging screening of patients with suspected coronary artery disease could safely avoid invasive procedures in 75 out of 100 patients. The study will have sufficient power to answer the question of which is the most cost-effective non-invasive imaging strategy for the j
February 2010 Br J Cardiol 2010;17:13-18
BJCardio editorial staff
ARBITER 6: niacin superior to ezetimibe for slowing atherosclerosis Use of extended-release niacin resulted in a significant benefit on atherosclerosis compared with ezetimibe in patients already taking statins in the ARBITER 6-HALTS trial. The trial, presented at the meeting by Dr Allen Taylor (Medstar Research Institute, Washington DC, US), compared two distinct lipid-modifying strategies in patients with known vascular disease already on statins who had LDL-cholesterol levels <100 mg/dL (2.56 mmol/L) and moderately low HDL-cholesterol levels (<50 mg/dL [1.28 mmol/L]). Among the 363 patients enrolled in the study, half were randomised
January 2007 Br J Cardiol 2007;14:57-60
Jo Waters
No content available
November 2006 Br J Cardiol 2006;13:434-40
Vivencio Barrios, Carlos Escobar, Alberto Calderón, Angel Navarro, Luis M Ruilope
No content available
September 2006 Br J Cardiol 2006;13:329-31
Helen Rivas-Toro
No content available
March 2006 Br J Cardiol 2006;13:113-20
Colin Waine
No content available
July 2005 Br J Cardiol 2005;12:283-90
Amit KJ Mandal, Constatinos G Missouris
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits